• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Cantor Fitzgerald initiated coverage on Hyperion Defi with a new price target

    12/16/25 8:52:58 AM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HYPD alert in real time by email
    Cantor Fitzgerald initiated coverage of Hyperion Defi with a rating of Overweight and set a new price target of $4.00
    Get the next $HYPD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HYPD

    DatePrice TargetRatingAnalyst
    12/24/2025Buy
    Chardan Capital Markets
    12/16/2025$4.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $HYPD
    SEC Filings

    View All

    SEC Form 424B3 filed by Hyperion DeFi Inc.

    424B3 - HYPERION DEFI, INC. (0001682639) (Filer)

    1/9/26 4:30:55 PM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hyperion DeFi Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - HYPERION DEFI, INC. (0001682639) (Filer)

    1/5/26 5:30:29 PM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hyperion DeFi Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - HYPERION DEFI, INC. (0001682639) (Filer)

    12/10/25 6:40:03 AM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HYPD
    Leadership Updates

    Live Leadership Updates

    View All

    Hyperion DeFi Appoints Hyunsu Jung as Chief Executive Officer

    Board Confirms Leadership Team to Execute 2026 Strategic Priorities Company Also Appoints Robert Rubenstein as General Counsel LAGUNA HILLS, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ:HYPD) ("Hyperion DeFi" or the "Company") today announced that its Board of Directors has appointed Hyunsu Jung as Chief Executive Officer, effective immediately. Mr. Jung's appointment marks an important milestone in the Company's leadership evolution as it advances its strategic priorities for 2026. Mr. Jung joined Hyperion DeFi as Chief Investment Officer in June 2025, where he has focused on developing on-chain business lines, strengthening operational discipline, and expandin

    1/5/26 8:00:00 AM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hyperion DeFi Announces Appointment of David Knox as Chief Financial Officer

    PayPal's Former Head of Capital Markets and Head of Finance for Global Credit and Financial Services Joins Company Strong Advocate for Blockchain Adoption for Traditional Institutional Financial Products LAGUNA HILLS, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ: HYPD) ("Hyperion DeFi" or the "Company"), the first U.S. publicly listed company building a long-term strategic treasury of Hyperliquid's native token, HYPE, today announced the appointment of David Knox, CFA, as Chief Financial Officer, effective immediately. This move is part of a broader strategic initiative to strengthen governance and accelerate the Company's decentralized finance ("DeFi") strateg

    9/29/25 8:00:00 AM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HYPD
    Financials

    Live finance-specific insights

    View All

    Hyperion DeFi Schedules Third Quarter 2025 Earnings Call for November 13, 2025

    LAGUNA HILLS, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ:HYPD) ("Hyperion DeFi" or the "Company"), the first U.S. publicly listed company dedicated to building a long-term strategic treasury of Hyperliquid's native token, HYPE, today announced that it will hold its earnings conference call and webcast for the third quarter ended September 30, 2025, on Thursday, November 13, 2025 at 5:00 p.m. Eastern Time. A press release detailing these results will be issued prior to the call on the same day. Participants may submit questions in advance of the call via email to [email protected]. A webcast of the call will be archived and available through Thursday, Novembe

    11/3/25 4:00:00 PM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hyperion Defi to Report Second Quarter 2025 Results on Wednesday, August 13, 2025

    NEW YORK, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Hyperion Defi, Inc. (NASDAQ:HYPD), the first U.S. public company to build a strategic treasury around the HYPE token and a pioneer in integrating decentralized finance with traditional corporate treasury strategies, will host its second quarter 2025 earnings call on Wednesday, August 13, 2025, at 4:30 p.m. to review the financial and operating results. Participants should dial 1-877-407-9039 (domestic) or 1-201-689-8470 (international) with the conference code 13754799. A live webcast of the conference call will also be available here as well as on the investor relations page of the Company's corporate website at Hyperion Defi. To access the Ca

    8/8/25 4:05:00 PM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HYPD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Hyperion DeFi Appoints Hyunsu Jung as Chief Executive Officer

    Board Confirms Leadership Team to Execute 2026 Strategic Priorities Company Also Appoints Robert Rubenstein as General Counsel LAGUNA HILLS, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ:HYPD) ("Hyperion DeFi" or the "Company") today announced that its Board of Directors has appointed Hyunsu Jung as Chief Executive Officer, effective immediately. Mr. Jung's appointment marks an important milestone in the Company's leadership evolution as it advances its strategic priorities for 2026. Mr. Jung joined Hyperion DeFi as Chief Investment Officer in June 2025, where he has focused on developing on-chain business lines, strengthening operational discipline, and expandin

    1/5/26 8:00:00 AM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hyperion DeFi Announces Receipt of Kinetiq Airdrop, Partnership with Native Markets, and Purchase of 150,000 Additional HYPE

    Receives 1,918,478.78 KNTQ in the Token Generation Event Airdrop, Plus Right to Earn Additional Yield on 28,888 HYPE Staked by the Company Partnership with Native Markets to Support Hyperliquid-Aligned USDH Stablecoin Generates Additional Yield for 300,000 HYPE Staked by the Company Announces 150,000 HYPE purchase resulting in 1,862,195 Gross HYPE Tokens Owned by the Company LAGUNA HILLS, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ:HYPD) ("Hyperion DeFi" or the "Company"), today announced a series of updates demonstrating its ongoing digital asset treasury growth and strong forward momentum across its DeFi strategy, including new yield opportunities, expanded e

    12/4/25 8:00:00 AM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hyperion DeFi Reports Third Quarter 2025 Financial Results with Record Net Income of $6.6 Million

    Management Initiates Q4'25 Adjusted Revenue(3) Guidance of 31% to 43% Q-o-Q Growth Over 13 Million HYPE Tokens Staked to Hyperion's Validator as of October 31, 2025 Ramping Business Lines Expected to Achieve Positive Operating Cash Flows in 2026 LAGUNA HILLS, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ:HYPD) ("Hyperion DeFi" or the "Company"), the first U.S. publicly listed company building a long-term strategic treasury of Hyperliquid's native token, HYPE, today reported results for the third quarter ending September 30, 2025. "This has been an extraordinary six months for Hyperion DeFi, and we are still in the early stages of our evolution," said Hyunsu Jung

    11/13/25 4:05:00 PM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HYPD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Knox David R. bought $100,340 worth of shares (27,950 units at $3.59), increasing direct ownership by 9% to 327,950 units (SEC Form 4)

    4 - HYPERION DEFI, INC. (0001682639) (Issuer)

    1/5/26 8:00:09 AM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Strahlman Ellen R bought $113,091 worth of shares (30,880 units at $3.66), increasing direct ownership by 21% to 91,161 units (SEC Form 4)

    4 - HYPERION DEFI, INC. (0001682639) (Issuer)

    12/30/25 4:01:21 PM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Strahlman Ellen R bought $120,664 worth of shares (38,444 units at $3.14), increasing direct ownership by 33% to 75,448 units (SEC Form 4)

    4 - HYPERION DEFI, INC. (0001682639) (Issuer)

    12/22/25 8:15:26 AM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HYPD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Knox David R. bought $100,340 worth of shares (27,950 units at $3.59), increasing direct ownership by 9% to 327,950 units (SEC Form 4)

    4 - HYPERION DEFI, INC. (0001682639) (Issuer)

    1/5/26 8:00:09 AM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Strahlman Ellen R bought $113,091 worth of shares (30,880 units at $3.66), increasing direct ownership by 21% to 91,161 units (SEC Form 4)

    4 - HYPERION DEFI, INC. (0001682639) (Issuer)

    12/30/25 4:01:21 PM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Jung Hyunsu covered exercise/tax liability with 82,324 shares, decreasing direct ownership by 5% to 1,417,676 units (SEC Form 4)

    4 - HYPERION DEFI, INC. (0001682639) (Issuer)

    12/30/25 4:00:22 PM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HYPD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Chardan Capital Markets initiated coverage on Hyperion Defi

    Chardan Capital Markets initiated coverage of Hyperion Defi with a rating of Buy

    12/24/25 11:52:07 AM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on Hyperion Defi with a new price target

    Cantor Fitzgerald initiated coverage of Hyperion Defi with a rating of Overweight and set a new price target of $4.00

    12/16/25 8:52:58 AM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care